• Vaccine Ontology ID: VO_0011368
• Type: Recombinant vector vaccine
• Status: Research
• H2-K1 gene engineering:
  • Type: Recombinant vector construction
  • Detailed Gene Information: Click Here.
• Vector: Recombinant adenovirus (Campbell et al., 2000).
• Immunization Route: i.t. injection

Rat Response

• Host Strain: Fisher 344
• Vaccination Protocol: A study was conducted to examine the growth inhibition of LN-4 tumors in vivo with an intratumoral (i.t.) injection of AdV-H-2Kb adenovirus. Fisher 344 rats were injected s.c. in their right thighs with 0.5x10^6 LN-4 tumor cells. At 2 weeks after tumor inoculation, when tumors grew to ;3–4 mm in diameter, rats were injected i.t. with a single dose of 2.5x10^9 PFU of the AdV-H2Kb virus. The i.t. injection of the AdV-H-2Kb virus was given two more times at 5-day intervals for a total of three injections. As a control, rats were injected i.t. with a single dose of 2.5x10^9 PFU of the AdV5LacZ adenovirus (Campbell et al., 2000).
• Efficacy: The expression of xenogeneic MHC class I antigen completely abolished the LN-4 tumorigenicity in rats, whereas the expression of allogeneic MHC class I antigen only partially reduced the MCA-26 tumorigenicity in mice. The immunized rats that experienced LN-4/H-2Kb tumor regression further developed protective immunity against a subsequent challenge of LN-4 cells. Adenovirus-mediated H-2Kb gene transfer in vivo can further significantly inhibit pre-established LN-4 tumors (Campbell et al., 2000).